Latest News and Press Releases

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sarclisa de Sanofi en formulation sous-cutanée approuvé au Japon pour les patients atteints de myélome multiple

STOCKHOLM, June 18, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce that an oral presentation was conducted for the Black Swan Research Initiative’s® (BSRI)...

STOCKHOLM, June 09, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the International Myeloma Working Group (IMWG) are proud to announce the recipients of this year’s Robert...

Sarclisa SC approved in EU: first anticancer via on-body injector CirCLIQ®. Flexible home/clinic administration for multiple myeloma patients.

Sarclisa SC approuvé en UE : 1er anticancéreux via injecteur corporel CirCLIQ®. Administration flexible domicile/clinique pour myélome multiple.

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- --...

Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.

STUDIO CITY, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announces its 3rd annual Iceland Cycling Expedition, taking place August 18-24, 2026, where...

STUDIO CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- As this year’s Myeloma Action Month came to a close, the International Myeloma Foundation (IMF) was truly grateful for the incredible support...